fig7

Fibroblast growth factor receptor alterations and resistance mechanisms in the treatment of pediatric solid tumors

Figure 7. Effect of FGFR inhibitor BGJ398 on neuroblastoma cell proliferation and survival. (A) Neuroblastoma cell lines (SK-N-AS, SK-N-SH, SK-N-BE(2), IMR-32, NGP, SH-SY5Y, LA155N, NBL-S, CHP134, Kelly, CHP212, and NB-10) were treated with increasing concentrations of BGJ398 for 72 h. Mean average values for a reduction in confluence (% inhibition) from triplicate experiments were then plotted in Microsoft Excel against BGJ398 dose levels; (B) IC50 values were calculated using curve-fit equations for each tested neuroblastoma cell line listed from lowest to highest IC50 values for each cell type; (C) Relative FGFR1-4 gene expression levels in cell lines were obtained by RNA-sequencing and were graphed in Microsoft Excel as fragments per kb of transcript per million fragments mapped (FPKM); and (D) FGFR gene member expression was compared to calculated IC50 values using Python Code software. FGFR: fibroblast growth factor receptor; BGJ398: infigratinib.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/